Why the first dose is deliberately too low to work

It is a different thing doing a different job, and that is the sentence most people never hear.

The dose you start on exists to let your digestive system adapt. These medicines slow gastric emptying, and introducing that effect at full strength produces nausea severe enough that a substantial number of people would stop in the first fortnight. Starting low and climbing slowly is how the therapeutic dose becomes reachable at all.

So the early weeks are not a weak attempt at weight loss. They are the preparation that makes weight loss possible later, and judging the treatment by what happens during them is like judging a flight by the taxiing.

Longer than most people expect, and the schedules are published rather than discretionary.

This is the strongest evidence that the early weeks are not meant to be judged, and it is hiding in the stopping rules.

Tirzepatide's review point — the formal question of whether treatment is working against a 5% threshold — falls six months after you reach the highest tolerated dose, not six months after your first injection. Liraglutide's falls 12 weeks after reaching 3.0 mg, not 12 weeks after starting.

In other words, the regulatory position is that the clock on "is this working" does not start until you are on a dose that could work. Someone who stops at week six has not had a disappointing result; they have had no result, because the thing being measured had not begun.

Something, usually — just not much of it on the scale, and not reliably.

Many people notice some appetite change within the first week or two, because even the starting dose does something. Some lose a few kilograms early, often partly water. Others notice nothing at all until the third or fourth dose step, and that is within the normal range rather than a sign of non-response.

What is more consistently noticeable is side effects, and they cluster in exactly this period: in the first weeks and after each increase. So the early experience can be the worst of both — the nausea has arrived and the benefit has not. Knowing that this is the designed shape of the thing, rather than evidence it is going badly, is most of what gets people through it.

The common sequence runs like this. Someone starts, tolerates the first weeks indifferently, sees little movement by week six or eight, concludes it is not working for them, and stops.

What they have actually done is pay for the uncomfortable part and leave before the part that was supposed to work. If they later restart, they start again at the bottom and repeat the same escalation — so the cost of stopping early is paid twice.

The useful reframe is that the first few months are an investment with a known payback point rather than a trial period. If the dose column in your weekly record shows you never reached the maintenance dose, nothing about your response has been tested yet.

None of this means the schedule is a race, and faster is not better.

If side effects are difficult at a given step, staying there longer is a legitimate clinical decision rather than a failure to progress. The schedules specify minimum intervals, not maximums, and a prescriber can hold you at a dose for as long as it takes.

What matters is that holding is a decision somebody made, recorded, and intends to revisit — not a drift. That is also why the dose and any holds belong in the record you take to a review: a flat result at a low dose and a flat result at the maximum tolerated dose mean entirely different things.